/ II trial of Novel Human Growth Hormone Product CandidateAmbrx.

, / II trial of Novel Human Growth Hormone Product CandidateAmbrx, today announced that it initiated a Phase I / II trial of ARX201, a novel, next-generation human growth hormone product candidate.The Phase I / II dose-finding study in adult patients with growth hormone deficiency will investigate the safety, tolerability, pharmacokinetic and pharmacodynamic profile of ARX201 following single and repeated dose escalation. Ambrx expects that the trial to the end of 2007 to complete. With ARX201, we believe that we can, a product that clearly benefit patients with growth hormone deficiency , by the frequency of dosing from daily to once weekly or even possibly develop even more rare and said Martin Mattingly, President CEO Ambrx.

About ARX201 – ‘s drug candidate Ambrx the ARX201 , a recombinant form of human growth hormone that has been modified using the company’s patented ReCODE technology to precise spatial positioning of the site of poly glycol to the. Biosynthetic incorporation of a chemically unique amino acid The Company believes that ARX201, pharmacological performance over existing growth hormone products, including requiring less frequent dosing have improved.SciClone Pharmaceuticals,SciClone Pharmaceuticals, Inc.S. Food and Drug Administration (FDA an agreement on an agreement on the designing from a phase 3 registration trial to thymalfasin as a possible treatment for stage IV melanoma.

Words such as expected to, plans, believes, may be, will, expects, and variants plans these terms or similar terms are intended to identification forward-looking statements. Addition, statements related to expectations, projections and other characterizations of future reflect events or circumstances, including all assumptions underlying related forward-looking statements forward-looking statements. These statements are not guarantees of future performance and subject to risks, uncertainties and assumptions who are difficult to predict and the actual results may differ materially. Such risks include changes in demand and sale of ZADAXIN, progress or failure in out of clinical studies, today announced true of experience in achieve our objectives, the capabilities of our partners, service of the independence and eligibility of written population of patients , unanticipated delays or additional expenditure our clinical trials, our clinical trials, our future financial requirements, delay in the analysis and synthesis of clinical trial data obtained the performance and any future actions our strategic partners, an unexpected delays in clinical degree enrollment, future actions by the U.S.

Related Posts

Other Posts From Category "potency":